Two neuroscience-facing studies underscored how RNA regulation can reshape neurodegeneration pathways. A transcriptomic aging-screen identified SRSF1 as a conserved regulator of aging, with overexpression reversing multiple hallmarks in human cells and extending median lifespan in mice by 14%. Separately, researchers reported that HuR acts as a master switch influencing tau exon 10 splicing and Alzheimer-relevant autophagy and apoptosis gene networks. Together, the work strengthens a growing theme: splicing regulators can control both proteostasis and disease-relevant signaling downstream of tau and neuroinflammation. For translational teams, these findings raise the possibility of developing RNA-splicing-targeted approaches—though any clinical strategy will require careful validation of target engagement, isoform specificity, and safety. The immediate impact for the biotech sector is a sharpened mechanistic rationale for exploring splicing modulation as a lever in Alzheimer’s and related tauopathies, with biomarkers and tissue-specific validation likely central to next-stage programs.